+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Irreversible loss of [3H]forskolin binding sites in human platelets by alpha-haloacetyl analogs of forskolin



Irreversible loss of [3H]forskolin binding sites in human platelets by alpha-haloacetyl analogs of forskolin



Molecular Pharmacology 37(1): 69-74



The 7-bromoacetyl-7-desacetyl (BrAcFsk) and 7-chloroacetyl-7-desacetyl (CIAcFsk) analogs of forskolin were synthesized as alkylating agents to study the high affinity binding sites for forskolin. BrAcFsk and CIAcFsk activated adenylate cyclase in human platelet membranes with EC50 values of about 20 and 12 microM, respectively. Both analogs increased cyclic AMP in human platelets; however, they were less potent that forskolin. Forskolin inhibited [3H]forskolin binding to human platelet membranes with an IC50 of 20 nM, whereas BrAcFsk and CIAcFsk inhibited [3H] forskolin binding with IC50 values of 0.1 microM. Pretreatment of intact platelets with 10 microM BrAcFsk caused a 90% irreversible loss in [3H]forskolin binding sites, whereas pretreatment with 10 microM CIAcFsk led to a loss of 55% of the binding sites. The loss of binding sites occurred within 5 min for BrAcFsk and within 30 min for CIAcFsk. The time required for the loss of binding sites produced by either alkylating agent was increased by the inclusion of 200 microM forskolin in the pretreatment buffer. The inactive bromoacetyl analog of forskolin 7-bromoacetyl-7-desacetyl-1.9-dideoxyforskolin (1,9-dideoxy-BrAcFsk) did not activate adenylate cyclase, inhibit [3H]forskolin binding, or cause an irreversible loss of [3H]forskolin binding sites. Adenylate cyclase was assayed in membranes from platelets treated with either 10 microM BrAcFsk or 10 microM 1,9-dideoxy-BrAcFsk. The stimulation of adenylate cyclase by prostaglandin E1, guanosine-5'-O-(3-thio)triphosphate, and AIF4 was inhibited by about 50% in membranes from platelets treated with BrAcFsk. However, the stimulation of adenylate cyclase by forskolin was unaffected by preincubation with BrAcFsk. Pretreatment of human platelets with 1,9-dideoxy-BrAcFsk had no effect on the stimulation of adenylate cyclase by prostaglandin E1, AIF4, or forskolin.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040507821

Download citation: RISBibTeXText

PMID: 2153911


Related references

Characterization of [3H]-forskolin binding sites in young and adult rat brain cortex: identification of suramin as a competitive inhibitor of [3H]-forskolin binding. Canadian Journal of Physiology and Pharmacology 83(7): 573-581, 2005

Forskolin-mediated activation of cardiac, liver and lung adenylate cyclase in the rat. Relation to [3H]forskolin binding sites. Biochemical Pharmacology 35(13): 2247-2251, 1986

Forskolin mediated activation of cardiac liver and lung adenylate cyclase in the rat relation to tritiated forskolin binding sites. Biochemical Pharmacology 35(13): 2247-2252, 1986

Effect of alpha 2 adrenergic agonist preincubation on subsequent forskolin stimulated adenylate cyclase and tritiated forskolin binding in ht29 cells. FASEB Journal 2(5): ABSTRACT 4901, 1988

Effects of alpha 2-adrenergic agonist preincubation on subsequent forskolin-stimulated adenylate cyclase activity and [3H]forskolin binding in membranes from HT29 cells. Biochemical Pharmacology 40(4): 871-877, 1990

Comparison of tritiated forskolin binding to forskolin specific antibodies and human platelet membranes. Federation Proceedings 46(4): 1296, 1987

Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin. Molecular Pharmacology 50(2): 299-305, 1996

Effects of alpha 2 adrenergic agonist preincubation on subsequent forskolin stimulated adenylate cyclase activity and tritiated forskolin binding in membranes from ht29 cells. Biochemical Pharmacology 40(4): 871-878, 1990

Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. Molecular Pharmacology 46(2): 329-337, 1994

Purification of an apparent forskolin binding protein by adsorption and elution from forskolin affinity column. Federation Proceedings 46(4): 1297, 1987

Experimental study on changes of intraocular pressure by the application of forskolin 3. binding to melanin and ocular toxicity of forskolin. Medical Journal of Hiroshima University 35(3): 179-188, 1987

Characterization of [3H]forskolin binding sites in the human caudate nucleus. Brain Research 610(1): 156-161, 1993

125I]-labeled forskolin analogs which discriminate adenylyl cyclase and a glucose transporter: pharmacological characterization and localization of binding sites in rat brain by in vitro receptor autoradiography. Journal of Pharmacology and Experimental Therapeutics 263(3): 1415-1423, 1992

Alpha-trinositol blocks the inhibitory effects of NPY on dilatation to forskolin but not the adenylyl cyclase activity induced by NPY or forskolin in guinea-pig cerebral vessels. Neuropeptides 27(5): 259-268, 1994

Quantitative autoradiography of guanine nucleotide binding sites comparison with the distribution of tritium forskolin binding sites. Society for Neuroscience Abstracts 11(1): 666, 1985